Hyperion DeFi Inc

Análisis de la acción Hyperion DeFi Inc (HYPD)

$2.510

-0.049 (-1.95%)Al cierre

Loading chart…
Máximo
2.671
Apertura
2.600
Precio medio ponderado por volumen
2.51
Volumen
427.17K
Capitalización
—
Mínimo
2.360
Importe
1.07M
EV/EBITDA, TTM
-0.88

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.

hyperiondefi.com

Análisis de IA of Hyperion DeFi Inc (HYPD)

Comprar

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

Métricas de valoración

El PER previsto actual de Hyperion DeFi Inc (HYPD) es 0.00, frente a su media de 5 años de -0.57.

PER previsto

Muy sobrevalorado
Media 5A P/E
-0.57
P/E actual
0.00
Sobrevalorada
-0.41
Infravalorada
-0.73

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-0.82
EV/EBITDA actual
-0.88
Sobrevalorada
-0.30
Infravalorada
-1.35

Precio/ventas previsto

Infravalorado
Media 5A P/S
13.87
P/S actual
6.77
Sobrevalorada
18.67
Infravalorada
9.06

Cronología de eventos

2026-10-02 (ET)

10:00:00

Coinbase Receives CFTC Approval for Derivatives Clearing

08:30:00

Hyperion DeFi Repurchases 240,124 HYPD Shares and Retires $8.6M Debt

2026-09-28 (ET)

09:30:00

Hyperion DeFi Named Launch Partner for Frontier's Hyperliquid Vault

2026-09-11 (ET)

10:00:00

Nasdaq to Invest $100M in Payward

2026-09-08 (ET)

09:00:00

Hyperion DeFi Launches $20M Share Buyback Program

Noticias

Preguntas frecuentes sobre HYPD, respondidas por Alphio AI

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles. It operates in the Healthcare sector.

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar